US-based diagnostic solutions provider Quidel has signed definitive agreements to buy Triage assets from point-of-care (POC) diagnostics firm Alere for around $400m and an additional $40m in contingent consideration.

The agreement includes the Triage MeterPro cardiovascular (CV) and toxicology assets, real estate for the Triage facilities at San Diego, US, and the B-type Naturietic Peptide (BNP) assay business.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The deal is expected to diversify Quidel’s overall business and bolster its presence in the POC market, while the combination of businesses will offer rapid diagnostics in critical care settings.

Alere is divesting the assets to obtain antitrust approvals that are required for its approximately $5.3bn acquisition by Abbott, estimated to be completed by the end of the third quarter of this year.

Quidel president and CEO Douglas Bryant said: “The Triage acquisition significantly stabilises our quarterly revenue profile and enhances our geographic and product diversity, with substantial expansion opportunities in new markets.

"The Triage acquisition significantly stabilises our quarterly revenue profile and enhances our geographic and product diversity, with substantial expansion opportunities in new markets."

“We believe there are substantial benefits to be realised as we bring these strong organisations together, further establishing Quidel’s platform for growth and shareholder value creation opportunities.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Quidel anticipates that the footprint of Triage MeterPro instruments in the country will complement its base of Sofia and Solana platforms in the hospital segment, while the Triage MeterPro system will offer access to its cardiac biomarker segment.

The firm intends to commercialise the Triage MeterPro products and BNP assays via direct sales force and distributors.

Expected to be closed by September, the Triage assets deal is subject to the completion of Abbott’s transaction, antitrust approvals and other customary closing conditions.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact